WhenType1IsCalledType2ByDefault.

The Type-1-in-kids, Type-2-in-adults heuristic is a teaching shortcut, not an accurate clinical rule. The actual epidemiology is more complex — roughly half of new Type 1 diabetes diagnoses occur in patients over age 20, and the latent autoimmune diabetes of adults form (LADA) can take years to progress to full insulin dependency. When the heuristic drives the diagnosis instead of the laboratory, the misdiagnosis pattern recurs.

The mechanism has four intersecting components:

• Age-based heuristic. Provider sees a 35-year-old with hyperglycemia and defaults to Type 2 because “they’re too old for Type 1.” The heuristic is wrong at scale — adult-onset Type 1 is not rare.
• Body habitus misreading. The Type 2 picture is associated with obesity and metabolic syndrome. A lean adult with new hyperglycemia should raise suspicion for Type 1 rather than default to Type 2, but providers sometimes do not register the atypical feature.
• LADA presents slowly. Unlike the acute Type 1 presentation in children (DKA within days to weeks of first symptoms), LADA can look like mildly elevated A1c with preserved insulin production for months. The patient seems to respond to metformin initially, which reinforces the Type 2 label — until they do not, and the beta-cell destruction catches up.
• Antibody testing not in routine workup. GAD-65, IA-2, ZnT8, and insulin autoantibodies are not part of the default new-diabetes panel. They have to be specifically ordered. When the provider does not consider Type 1, the antibody testing does not happen and the misdiagnosis persists until a DKA admission forces the correction.

The pattern is documented in endocrinology literature and is a recurring theme in malpractice cases involving adult-onset autoimmune diabetes. The case is typically built on a record that shows atypical features — lean habitus, rapid A1c progression, ketosis-proneness, family autoimmune history — that should have prompted antibody testing at the initial diagnosis but did not.

The American Diabetes Association Standards of Medical Care in Diabetes and the Endocrine Society guidance converge on the distinction between Type 1 and Type 2 at diagnosis. Core requirements when atypical features are present:

• Recognize atypical features. In an adult: lean body habitus, lack of metabolic syndrome features (normal BP, normal lipids, no acanthosis nigricans), rapid symptom progression, weight loss preceding diagnosis, ketosis on urinalysis or serum, family history of Type 1 or other autoimmune disease, personal history of other autoimmune disease (thyroiditis, celiac, Addison).
• Antibody testing. GAD-65 (glutamic acid decarboxylase), IA-2 (insulinoma antigen 2), ZnT8 (zinc transporter 8), insulin autoantibodies. A positive result confirms autoimmune etiology.
• C-peptide. Measures endogenous insulin production. Low C-peptide with hyperglycemia points toward Type 1. Normal or elevated C-peptide with hyperglycemia points toward Type 2 or insulin resistance.
• Appropriate initial treatment. Autoimmune Type 1 requires insulin from diagnosis. Delaying insulin in favor of oral agents risks progression to DKA.
• Pediatric considerations. In children, Type 1 is the default but not exclusive — monogenic diabetes (MODY), mitochondrial diabetes, and Type 2 in obese adolescents all occur. The workup still includes antibody testing.
• Reconsideration when oral agents fail. If a patient labeled Type 2 has rapidly rising A1c on appropriate oral therapy, weight loss, or ketosis, the diagnosis should be reconsidered and antibody testing should follow — not another oral agent added.

Compare what the record shows against what the standard requires. A chart documenting a lean adult with new diabetes, rapid A1c progression despite metformin, and no antibody testing is the clearest version of this case. A chart showing a positive ketone result that was not acted on is another. Florida malpractice cases for diabetes misdiagnosis are built on exactly these gaps.

DKA is the preventable injury at the center of most Type-1-misdiagnosed-as-Type-2 malpractice cases. Understanding the mechanism matters for the damages analysis:

• Pathophysiology. Absolute insulin deficiency leads the body to shift to fatty-acid metabolism, producing ketones (acetoacetate, beta-hydroxybutyrate) at rates that overwhelm buffering capacity. The resulting metabolic acidosis is compounded by osmotic diuresis from severe hyperglycemia, producing dehydration and electrolyte derangement (particularly hypokalemia on correction).
• Presentation. Kussmaul respirations, fruity breath, nausea and vomiting, abdominal pain, altered mental status ranging from fatigue to coma. Laboratory confirmation: hyperglycemia (typically greater than 250 mg/dL, but euglycemic DKA exists), anion gap metabolic acidosis, positive serum or urine ketones.
• Treatment. IV fluids (large volumes), insulin infusion, aggressive electrolyte replacement (potassium specifically), treatment of any precipitant (infection is common). ICU-level care is typical, with length of stay measured in days.
• Complications. Cerebral edema (particularly in pediatric DKA, significant mortality), acute kidney injury, thromboembolism, pulmonary complications. Severe or recurrent DKA can produce cognitive impairment.
• Mortality. DKA mortality is generally low in well-resourced settings but not zero — and cerebral edema complications in pediatric cases carry substantial mortality. Failure-to-rescue analysis in a DKA-related death can add a separate breach to the initial misdiagnosis.

Keep in mind that DKA is not a routine diabetes complication — it is a sentinel event that in new-onset diabetes often means the Type 1 diagnosis was missed. When a patient with a Type 2 label presents to an ER with DKA, the subsequent admission typically establishes the true Type 1 diagnosis. The malpractice question is whether the earlier workup should have caught it.

The SGLT2 inhibitor-induced euglycemic DKA phenomenon is a particularly clear subset of diabetes-misdiagnosis malpractice because the causal chain is explicit:

• The mislabeling. Patient diagnosed as Type 2 without antibody testing.
• The prescription. SGLT2 inhibitor added to the regimen (often as second-line after metformin, or for cardiovascular benefit).
• The mechanism. Renal glucose excretion masks hyperglycemia, but insulin deficiency still drives ketogenesis. The glucose looks acceptable while ketones rise.
• The presentation. Nausea, vomiting, abdominal pain, Kussmaul respirations — often with glucose in the low 200s or even normal range. Diagnostic delay can occur because the clinician does not see the expected severe hyperglycemia and does not think of DKA.
• The confirming diagnosis. Subsequent antibody testing reveals the autoimmune etiology and confirms the original diagnostic failure.

Note that SGLT2 inhibitors remain appropriate therapy for Type 2 diabetes and have major cardiovascular and renal benefits in the right patients. The failure is not the class — it is the prescription of an SGLT2 inhibitor in a patient whose Type 2 label was never verified, producing an entirely preventable DKA event.

These cases rest on a specific documentary foundation — what the initial record showed about the patient’s body habitus, symptoms, and risk profile, and what testing was or was not ordered based on those features. Key evidentiary sources:

• Initial diagnosis record. Height, weight, BMI, documented symptoms, body habitus notes, presence or absence of metabolic syndrome features, family history, personal autoimmune history, any ketosis or ketoacidosis at presentation.
• Initial workup. Glucose, A1c, lipid panel, renal function, and critically, whether antibody testing and C-peptide were ordered at diagnosis or at any subsequent visit.
• Treatment sequence. Initial oral agent, subsequent dose escalations, second and third agents added, SGLT2 inhibitor prescriptions if any, and the timing of each.
• Follow-up A1c and symptom trajectory. Rising A1c despite treatment, weight loss, polyuria, polydipsia — the documented deterioration that should have prompted reconsideration of the diagnosis.
• DKA hospitalization record. Admission labs, clinical status, ICU admission if applicable, antibody testing (typically performed during or after the DKA admission), C-peptide, confirming Type 1 diagnosis, transition to insulin.
• Post-discharge care. Insulin regimen, CGM or pump initiation, ongoing endocrinology follow-up, any permanent sequelae (cognitive testing if severe DKA, ophthalmology findings, nephrology involvement).

Florida Statute § 766.102 requires a corroborating expert affidavit before filing. The standard expert is a board-certified endocrinologist, typically with experience in both new-onset diabetes diagnosis and inpatient DKA management. For pediatric DKA cases, a pediatric endocrinologist and potentially a pediatric intensivist or neurologist (where cerebral edema produced permanent injury).

Damages in a diabetes misdiagnosis case depend on the severity of the DKA event and any permanent injury. Cases without permanent injury — a single DKA admission with full recovery — carry different values than cases with cognitive sequelae from cerebral edema or fatal outcomes.

• Past medical expenses for the DKA hospitalization, ICU care, and subsequent treatment restructuring.
• Future medical expenses for lifetime insulin therapy, CGM and pump technology, ophthalmology and nephrology surveillance, management of any permanent complications.
• Lost earnings during hospitalization and recovery.
• Lost earning capacity where permanent cognitive or physical injury results from severe DKA.
• Pain and suffering, including the DKA event itself and the chronic burden of managing diabetes with an earlier, preventable crisis.
• Loss of consortium for spouse.

Florida no longer caps non-economic damages in medical malpractice cases after North Broward Hospital District v. Kalitan, 219 So. 3d 49 (Fla. 2017).

Florida Statute § 95.11(4)(b) governs medical malpractice limitations: two years from discovery of the injury, four-year outer limit, seven years in cases of fraud or concealment. Wrongful death claims (particularly pediatric DKA cerebral edema fatalities) have a separate two-year statute under Florida’s Wrongful Death Act, running from the date of death. The 90-day pre-suit investigation and § 766.102 expert affidavit requirements apply.